|Awarded On||February 19, 2020|
|Title||Off the shelf, Cord-Derived iNK T cells Engineered to Prevent GVHD and Relapse After Hematopoietic Stem Cell Transplantation|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jin Seon Im|
Allogeneic stem cell transplantation (ASCT) is only curative treatment for several blood cancer such as leukemia and lymphoma, and works through high dose chemotherapy to eradicate blood cancer in combination of donor immune system fighting against blood cancer. However, it is not offered to every patient who need because of high risk of developing transplant related complication such as Graft-Versus-Host-Disease (GVHD) where donor immune system attacks recipient’s body. Moreover, blood cancer may come back even after transplantation. Thus, an innovative therapy to prevent both GVHD and relapse of blood cancer is needed to improve the success rate of ASCT. Here, we propose to develop a n...